Prenatal and infant paracetamol exposure and development of asthma:the Norwegian Mother and Child Cohort Study by Magnus, Maria et al.
                          Magnus, M., Karlstad, O., Haberg, S., Nafstad, P., Davey Smith, G., &
Nystad, W. (2016). Prenatal and infant paracetamol exposure and
development of asthma: the Norwegian Mother and Child Cohort Study.
International Journal of Epidemiology, 45(2), 512-522. DOI:
10.1093/ije/dyv366
Peer reviewed version
Link to published version (if available):
10.1093/ije/dyv366
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Oxford University Press at https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyv366. Please refer to
any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
For Review Only
 
 
 
 
 
 
Prenatal and Infant Paracetamol Exposure and 
Development of Asthma: the Norwegian Mother and Child 
Cohort Study 
 
 
Journal: International Journal of Epidemiology 
Manuscript ID IJE-2015-06-0741.R1 
Manuscript Type: Original Article 
Date Submitted by the Author: n/a 
Complete List of Authors: Magnus, Maria; Norwegian Institute of Public Health, Department of 
Chronic Diseases 
Karlstad, Øystein; Norwegian Institute of Public Health, Department of 
pharmacoepidemiology 
Håberg, Siri; Norwegian Institute of Public Health, Institute Management 
and Staff 
Nafstad, Per; University of Oslo, Department of Community Medicine 
Davey Smith, George; University of Bristol, MRC Integrative Epidemiology 
Unit 
Nystad, Wenche; Norwegian Institute of Public Health, Department of 
Chronic Diseases 
Key Words: asthma, epidemiology, ibuprofen, paracetamol 
  
 
 
For Review Only
1 
 
Prenatal and Infant Paracetamol Exposure and Development of Asthma: the Norwegian 
Mother and Child Cohort Study 
 
Maria C Magnus 
1*
, Øystein Karlstad 
2
, Siri E Håberg 
3
, Per Nafstad 
1,4
 , George Davey Smith 
5
  & Wenche Nystad 
1
 
 
1
 Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.  
2
 Department of Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo, Norway.  
3
 Institute Management and Staff, Norwegian Institute of Public Health, Oslo, Norway. 
4
 Department of Community Medicine, Medical Faculty, University of Oslo, Oslo, Norway.  
5
 MRC Integrative Epidemiology Unit at the University of Bristol, School of Social and 
Community Medicine, Bristol, United Kingdom. 
 
* Corresponding author. Department of Chronic Diseases, Division of Epidemiology, 
Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, 0403 Oslo, Norway. E-mail: 
Maria.Christine.Magnus@fhi.no  
 
Word count: Abstract 249 words; Manuscript 3,150 words 
Tables and figures: 4 tables, 1 figure and 7 supplementary tables 
Medical subject headings: asthma, epidemiology, ibuprofen, paracetamol 
 
 
  
Page 1 of 28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
2 
 
Funding:  
The data collection in the Norwegian Mother and Child Cohort Study is supported by 
National Institutes of Health [National Institute of Environmental Health Sciences contract 
number N01-ES-75558, National Institute of Neurological Disorders and Stroke grant no.1 
UO1 NS 047537-01 and grant no.2 UO1 NS 047537-06A1] and the Norwegian Research 
Council/FUGE [grant number 151918/S10]. This work was supported by the Norwegian 
Research Council [grant number 221919] and the Norwegian Extra-Foundation for Health and 
Rehabilitation [grant number 2011.2.0218 to M.C.M.]. The funding sources had no role in the 
study design; the collection, analysis and interpretation of data; and the writing of the article 
and the decision to submit it for publication.  
 
Key messages: 
• Prenatal and infant paracetamol exposure was independently associated with asthma 
development after adjusting for common indications. 
• We compared associations between several conditions during pregnancy, with and 
without the use of paracetamol, and asthma development in the offspring. Our findings 
suggest that the associations could not be fully explained by confounding by indication. 
• Maternal use of paracetamol outside of pregnancy and paternal use of paracetamol did 
not show associations with asthma development in the offspring, indicating little 
influence by unmeasured characteristics reflected in the propensity for using 
paracetamol.    
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Abstract 
 
Background: Paracetamol exposure has been positively associated with asthma development. 
The relative importance of prenatal versus infant exposure and confounding by indication 
remains elusive. We examined the association of prenatal and infant (first 6 months) 
paracetamol exposure with asthma development while addressing confounding by indication. 
Methods: We used information from the Norwegian Mother and Child Cohort Study, 
including 53,169 children for evaluation of current asthma at 3 years, 25,394 for current 
asthma at 7 years, and 45,607 for dispensed asthma medications at 7 years in the Norwegian 
Prescription Database. We calculated adjusted relative risks (adj.RR) and 95% confidence 
intervals (CI) using log-binomial regression.  
Results: There were independent modest associations between asthma at 3 years with 
prenatal paracetamol exposure (adj.RR 1.13; 95 % CI: 1.02-1.25) and use of paracetamol 
during infancy (adj.RR 1.29; 95% CI: 1.16-1.45). The results were consistent for asthma at 7 
years. The associations with prenatal paracetamol exposure were seen for different indications 
(pain, respiratory tract infections/influenza and fever). Maternal pain during pregnancy was 
the only indication that showed an association both with and without paracetamol use. 
Maternal paracetamol use outside of pregnancy or paternal paracetamol use was not 
associated with asthma development. In a secondary analysis, prenatal ibuprofen exposure 
was positively associated with asthma at 3 years but not asthma at 7 years.  
Conclusions: This study provides evidence that prenatal and infant paracetamol exposure 
have independent associations with asthma development. Our findings provided suggest that the 
associations could not be fully explained by confounding by indication.   
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Introduction  
Asthma is the most common chronic disease during childhood.(1, 2) Prenatal and 
infant paracetamol exposure is proposed to be positively associated with asthma.(3-5) 
However, few previous studies were able to evaluate the relative importance of prenatal 
versus infant paracetamol exposure.(6-8) Paracetamol is the recommended 
analgesic/antipyretic for pregnant women and infants.(9) If the observed associations reflect 
true underlying effects, this is a public health concern. A limited number of previous studies 
of prenatal paracetamol exposure and asthma development considered confounding by 
indication.(7, 10, 11)  
An inherent limitation in observational studies is the possibility of unmeasured 
confounding. One approach to examine whether associations in observational studies might 
reflect unmeasured characteristics influencing the propensity for exposure is to use negative 
controls.(12, 13) Examples of negative controls include maternal use of paracetamol outside 
of pregnancy and the father’s use of paracetamol. If the associations are similar for maternal 
paracetamol use outside of pregnancy and paternal paracetamol use, it is likely that 
confounding by genetic or shared environmental characteristics is present.(12, 13)  
The objective of the study was thus to examine the association of prenatal and infant 
paracetamol exposure with asthma development while addressing confounding by indication. 
To further assess whether the previously reported associations reflected unmeasured 
confounding, we evaluated maternal paracetamol use outside of pregnancy and paternal 
paracetamol use. Since ibuprofen is used for many of the same indications as paracetamol, we 
also evaluated the association between prenatal ibuprofen exposure and asthma development. 
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Methods 
Study population 
We used data from the Norwegian Mother and Child Cohort Study (MoBa) conducted 
by the Norwegian Institute of Public Health.(14, 15) MoBa recruited pregnant women 
between 1999 and 2008, at approximately 18 weeks gestation. The participation rate of 
invited pregnant women was 40.6%. Mothers could participate with more than one pregnancy, 
resulting in approximately 95,200 mothers and 114,500 children. All participants gave a 
written informed consent. In May 2014, the 114,761 children participating in MoBa were 
linked to the Medical Birth Registry of Norway (henceforth called “birth registry”) and the 
Norwegian Prescription Database (henceforth called “prescription registry”). Children not 
linked to the birth registry (n=499) and children from multiple births (n=3,971) were not 
eligible for the current study. We used information from the MoBa questionnaires completed 
at 18 and 30 gestational weeks, and when the child was 6 months, 3 years and 7 years. The 
Norwegian Data Inspectorate and the Regional Ethics Committee for Medical Research of 
South/East Norway approved this study. 
 
Exposures 
 Participating mothers reported the use of medications for different indications during 
pregnancy through questionnaires completed at 18 gestational weeks, 30 gestational weeks 
and when the child was 6 months old. The mother was asked if she had experienced the 
disease/symptom of interest, and to list the medications she had used for that specific 
disease/symptom. The mother also listed the child’s use of medications during the first 6 
months of life. Medications were coded using the Anatomical Therapeutic Chemical 
classification system (ATC). Medications containing paracetamol (N02BE01, N02AA59, 
N02AX52 and N02BE51) were extracted. Three of the medications contained other active 
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ingredients, namely codeine (N02AA59), tramadol (N02AX52) and caffeine (N02BE51). To 
distinguish between prenatal versus infant paracetamol exposure, we classified mutually 
exclusive exposure categories: no exposure, prenatal exposure only, infant exposure only, 
both prenatal and infant exposure.  
 
Outcomes 
We examined two asthma outcomes based on the MoBa questionnaires and one 
outcome based on dispensed asthma medications: 1) We defined current asthma at 3 years as 
a “yes” in response to current asthma in combination with use of short- or long-acting beta 
(2)-agonists (R03AC) and/or inhaled corticosteroids (R03BA) in the past year reported in the 
3 year questionnaire. 2) Current asthma at 7 years was defined according to three positive 
criteria reported in the 7 year questionnaire: a positive report of ever asthma, experiencing 
asthma symptoms the past year and using medications for asthma in the past year. 3) A 
separate asthma definition at age 7 was based on information from the prescription registry. A 
child was regarded as having asthma if he/she had a dispensed asthma medication during the 
past year in addition to a second dispensed prescription within one year after the first. Asthma 
medications included R03AC, R03BA, R03AK, and R03DC. 
 
Other variables 
Maternal characteristics included age, parity, education, pre-pregnancy body mass 
index (weight in kilograms divided by measured height in meters squared), smoking during 
pregnancy, asthma, respiratory tract infections/influenza during pregnancy, pain during 
pregnancy, fever during pregnancy and use of antibiotics during pregnancy. Child 
characteristics included the child’s gender, birth weight, breastfeeding the first 6 months, 
respiratory tract infections the first 6 months, body mass index at 6 months and use of 
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antibiotics the first 6 months. We classified antibiotics for systemic use based on ATC codes 
J01A-J01X.   
   
Statistical analyses 
The analysis consisted of several steps. First, we examined the associations between 
prenatal and infant paracetamol exposure with asthma development using log-linear 
regression, reporting relative risks (RR) and 95% confidence intervals (CI). The multivariable 
analyses adjusted for all the potential confounding factors in Table 1. We used cluster 
variance estimation to account for siblings in the analyses. In order to evaluate whether 
maternal history of asthma was an effect modifier on the multiplicative scale, we included 
product terms in the multivariable regression models.   
Secondly, we evaluated the likelihood of confounding by indication by focusing on 
three common indications for use of paracetamol in pregnancy: pain, fever and respiratory 
tract infections/influenza. There was little a priori evidence that maternal pain during 
pregnancy might be associated with asthma development in the offspring. However, we 
wanted to evaluate whether maternal use of paracetamol for different/partly unrelated 
indications yielded similar associations with asthma development in the offspring. We 
categorized mutually exclusive exposure categories of mothers who had experienced the 
different indications with and without the use of paracetamol. In order to evaluate whether 
these maternal indications acted as effect modifiers on the multiplicative scale, we included 
product terms in the multivariable regression models. Third, we conducted sensitivity 
analyses to explore unmeasured confounding by background factors influencing the 
propensity of paracetamol exposure by examining maternal use of paracetamol the last 6 
months before pregnancy, maternal use of paracetamol the first 6 months after pregnancy and 
the father’s paracetamol use.  
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Fourth, since paracetamol and ibuprofen are used for similar indications, information 
about maternal use of ibuprofen during pregnancy was extracted (M01AE01). We 
subsequently evaluated prenatal exposure to paracetamol and ibuprofen in combination 
(neither, only ibuprofen, only paracetamol, both ibuprofen and paracetamol), to evaluate 
whether maternal use of these two medications during pregnancy yielded the same association 
with asthma development.  
There were approximately 10-15% of observations with missing information in the 
multivariable analyses. We therefore conducted multiple imputation by chained equations, 
imputing a total of 20 datasets.  
All of the p-values presented are two-sided. We conducted the analyses using Stata 
version 13 (Statacorp, Texas).  
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Results 
 A total of 53,169 children were included in the analysis of current asthma at 3 years, 
25,394 in the evaluation of current asthma at 7 years, and 45,607 in the evaluation of 
dispensed asthma medications at 7 years (Figure 1). The characteristics among individuals 
with and without the necessary follow-up information are given in Supplementary Table 1. A 
total of 27.9% of children were only exposed to paracetamol during pregnancy, 15.5% only 
during infancy, while 19.1% were exposed both during pregnancy and infancy. The 
distribution of characteristics by prenatal and infant paracetamol exposure is given in Table 1 
(Table 1 here).  
A total 5.7% of children had current asthma at 3 years, 5.1% had current asthma at 7 
years while 4.8% had dispensed asthma medications at 7 years. There were independent 
associations between asthma at 3 years with prenatal paracetamol exposure (adj.RR 1.13; 95 
% CI: 1.02-1.25) and use of paracetamol during infancy (adj.RR 1.29; 95% CI: 1.16-1.45) 
(Table 2) (Table 2 here). Similar results were observed for current asthma at 7 years and 
dispensed asthma medications at 7 years (Table 2).  
There was no strong evidence of multiplicative interaction between prenatal and infant 
paracetamol exposure on asthma development (p-values interaction >0.07). Separate analyses of 
prenatal and infant paracetamol exposure with asthma development are included in 
Supplementary Table 2. The results indicated a slightly stronger association between children 
exposed to paracetamol during two time periods of pregnancy with asthma development 
(Supplementary Table 2). 
 Our findings indicated evidence of an interaction by maternal history of asthma on the 
association between infant paracetamol exposure and asthma at 3 years (p-value interaction 
<0.01) (Supplementary Table 3). However, there was no strong evidence of an interaction by 
maternal history of asthma for the association between prenatal paracetamol and asthma 
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development, or the association between infant paracetamol exposure and the asthma 
outcomes at 7 years (p-values interaction > 0.1) (Supplementary Table 3). 
 We evaluated respiratory tract infections/influenza, fever and pain during pregnancy as 
common indications for using paracetamol. Prenatal paracetamol exposure for these three 
indications yielded similar associations with asthma development (Table 3) (Table 3 here). 
Furthermore, pain showed a positive association with asthma development without the use of 
paracetamol (Table 3). The strongest association was seen if the mother used paracetamol 
during pregnancy for more than one indication, adj.RR 1.94 (95% CI: 1.58-2.37) for current 
asthma at 3 years (Table 3). In order to further evaluate the potential role of confounding by 
indication, we conducted stratified analyses of the association between prenatal paracetamol 
exposure and asthma development by the three indications in turn (Supplementary Table 4). 
The results indicated no strong evidence of multiplicative interaction (p-values interaction >0.3). 
Likewise, we also conducted a stratified analysis of the association between infant 
paracetamol exposure and asthma development by the child’s experience of respiratory tract 
infections the first 6 months of life (Supplementary Table 5). The results indicated no 
evidence of multiplicative interaction (p-values interaction >0.5). There was no strong evidence 
of an association between paternal paracetamol use and asthma in the offspring 
(Supplementary Table 6). Likewise, maternal paracetamol use during the last 6 months before 
pregnancy, or the first 6 months after delivery, showed no strong evidence of an association 
with asthma in the offspring (Supplementary Table 6).  
Prenatal exposure to ibuprofen was only reported for 5.8% of children. Prenatal 
exposure to ibuprofen only (no exposure to paracetamol) showed some evidence of an 
association with current asthma at 3 years, adj.RR 1.31 (95% CI: 1.00,1.72), while there was 
weak evidence for a positive association with current asthma at 7 years and dispensed asthma 
medications at 7 years (Table 4) (Table 4 here).  
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The results from the multiple imputation analyses were similar to the complete case 
analyses (Supplementary Table 7). A sensitivity analysis of prenatal paracetamol exposure 
excluding mothers who had reported multiple medications and indicated multiple time periods 
(during and outside of pregnancy), approximately 9% of mothers, also indicated similar 
associations (data not shown).  
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Discussion 
 This large-scale prospective observational study indicated that both prenatal and infant 
paracetamol exposure showed independent positive associations with asthma development. 
Furthermore, the association between prenatal paracetamol exposure and asthma development 
was similar if used for respiratory tract infections/influenza, fever or pain. Prenatal ibuprofen 
exposure was only associated with an early asthma phenotype.  
 
Comparison with previous studies 
 Our finding that prenatal and infant paracetamol exposure is positively associated with 
asthma development is largely in accordance with results summarized in meta-analyses.(3-5) 
However, most studies in these meta-analyses did not address confounding by indication.   
Of the three previous studies examining prenatal paracetamol exposure and asthma 
development that adjusted for infections/antibiotics during pregnancy, all reported a positive 
association.(7, 10, 11) The magnitude of the associations in these studies ranged between 1.15 
to 1.29.(7, 10, 11) Among previous studies of infant paracetamol exposure and asthma 
development that adjusted for the child’s experience of respiratory tract infections (6, 8, 16-
19), three studies reported a positive association (6, 16, 19). These studies reported that 
paracetamol exposure during infancy was associated with a doubling in the risk of asthma 
development.(6, 16, 19) However, one of these studies indicated that the association was 
restricted to girls.(6) Our study is the first to evaluate the relative importance of prenatal 
versus infant paracetamol exposure able to account for common indications during both 
exposure periods. This allowed us to show that both prenatal and infant paracetamol exposure 
had independent positive associations with asthma development after adjustment for 
confounding by indication during both exposure periods. 
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Two previous studies examined prenatal ibuprofen exposure and asthma development. 
(8, 11) One of these studies examined both prenatal and infant ibuprofen exposure, reporting a 
positive association with infant ibuprofen exposure, adjusted odds ratio 1.20 (95 % 
confidence interval 1.02 to 1.40), but no strong evidence of an association with prenatal 
ibuprofen exposure, 1.17 (0.78-1.76).(8) Our results indicated a weak evidence for a positive 
association between prenatal ibuprofen exposure with asthma at 3 years and no strong 
evidence for an association with asthma at 7 years. We could not evaluate infant ibuprofen 
exposure as too few were exposed (0.1%).  
 
Interpretation of main findings 
 Pregnant women who have asthma might be more likely to choose paracetamol as an 
analgesic/antipyretic compared to acetylsalicylic acid and other nonsteroidal anti-
inflammatory drugs due to sensitization.(20) However, our results provided no strong 
evidence of an effect modification of maternal history of asthma on the observed associations.  
This is the first study to address maternal conditions in pregnancy with and without the 
use of paracetamol in relation to asthma in the offspring. Maternal paracetamol use for 
respiratory tract infections/influenza, fever or pain all showed a positive association with 
asthma in the offspring, while maternal report of pain was the only indication that was 
positively associated with asthma in the offspring if the mother did not use paracetamol. Pain 
is highly subjective and likely influenced by a number of factors, and these findings therefore 
need to be replicated and explored in depth.  One might speculate that maternal pain during 
pregnancy is a potential source of stress. A possible explanation for our finding is therefore 
the association between prenatal exposure to stress and asthma development.(21-24) 
However, our observed associations of prenatal and infant paracetamol exposure with asthma 
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development might also reflect the severity of the condition leading to paracetamol use. It was 
not possible to further evaluate this using the information available.  
We cannot exclude the possibility that the association of prenatal and infant 
paracetamol exposure with asthma development might be partly mediated by later 
paracetamol exposure. 
The evaluation of maternal paracetamol use outside of pregnancy and paternal 
paracetamol use was motivated by a negative controls approach.(12, 13) Evaluation of these 
negative controls allowed an assessment of the likelihood of unmeasured confounding by 
characteristics that might influence the propensity for using paracetamol. Only one study has 
previously evaluated maternal paracetamol use after pregnancy and paternal paracetamol 
use.(25) In line with the findings from this previous study, we found no strong evidence for an 
association between maternal paracetamol use outside of pregnancy or paternal paracetamol 
use with asthma in the offspring, supporting the conclusion that the results were not caused by 
underlying characteristics or health behavior.  
If the observed association between paracetamol exposure and asthma development 
reflects a true effect, proposed biological mechanisms include the ability of paracetamol to 
induce oxidative stress, enhance Th2 cell polarization and mediation of non-eosinophilic 
inflammatory responses.(26, 27) Increased oxidative stress during pregnancy and infancy is 
hypothesized to increase the risk of asthma.(28) This hypothesis is also supported by studies 
reporting an inverse association between maternal antioxidant intake during pregnancy and 
asthma in the offspring.(29, 30) Results from the Avon Longitudinal Study of Parents and 
Children also indicate that maternal antioxidant gene polymorphism may modify the 
association between prenatal paracetamol exposure and asthma development.(7) 
Ibuprofen is used for many of the same indications as paracetamol. According to Norwegian 
guidelines , ibuprofen is not recommended for pregnant women and infants who weigh less 
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than 10 kilograms.(9)  Based on our results, we could not conclude with certainty that prenatal 
ibuprofen exposure did not have a similar positive association with asthma development as 
observed for prenatal paracetamol exposure, since we likely had limited power to detect an 
association with our outcomes at 7 years. Ibuprofen is a COX-1 inhibitor, contributing to an 
up-regulation of leukotrienes, thought to play a role in asthma pathogenesis.(31)  
Strengths and limitations 
 Strengths of the current study include the size, detailed evaluation of different 
indications for prenatal paracetamol exposure, evaluation of prenatal ibuprofen exposure, in 
addition to the evaluation of maternal paracetamol use outside of pregnancy and paternal 
paracetamol use as negative controls. This is the first study comparing the association 
between prenatal exposure to different indications and use of paracetamol for different 
indications with development of asthma, and the first study examining the relative importance 
of prenatal versus infant paracetamol exposure in relation to asthma development that was 
able to adjust for confounding by indication during both exposure periods.  
The main limitation of the information available in MoBa was the ability to account 
for the amount paracetamol used and severity of the underlying indications. However, by 
evaluating prenatal paracetamol exposure for more than one i dication and during more than 
one time period of pregnancy, we evaluated two approaches to distinguish between amounts 
of exposure. The classification of prenatal and infant paracetamol exposure through 
questionnaires could have resulted in misclassification. Due to the prospective data collection, 
any misclassification of paracetamol exposure is unlikely to be differential by the child’s 
asthma status. Another limitation is that the information available for the child’s use of 
medications during the first 6 months of life did not include which specific condition the 
medications had been used for. By using maternal report of the child’s asthma status there 
may also be misclassification of the outcome. However, maternal report that the child used 
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asthma medications in the past year on the 7 years questionnaire in MoBa compared well to 
dispensed asthma medications in the prescription registry.(32)  A comparison of MoBa 
participants against all Norwegian women who gave birth during the inclusion period 
indicated that several high risk groups might be underrepresented.(15) This might influence 
the generalizability of our results.(33-35) Our study further required information from a 
number of follow-up questionnaires. A comparison of eligible individuals with and without 
the necessary follow-up information indicated that mothers of children with the necessary 
follow-up information were older, were more likely to have higher education and were less 
likely to smoke (Supplementary Table 1). We further evaluated bias due to loss to follow-up 
by using dispensed asthma medications as an additional outcome, which showed similar 
associations as the questionnaire based outcome.  
 
Conclusion 
 Our study is by far the largest study to provide evidence that prenatal and infant 
paracetamol exposure have independent positive associations with asthma development. Our 
findings provided suggest that the associations could not be fully explained by confounding by 
indication.  Paracetamol is the most commonly used analgesic/antipyretic among pregnant 
women and infants, and uncovering potential adverse effects is of public health importance. 
Based on the inherent challenges in observational studies, evidence from a randomized 
controlled trial would be beneficial.  
Page 16 of 28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
17 
 
Acknoweldgements 
Contributors: The study was initiated by M.C.M and W.N., and designed by M.C.M., W.N., 
S.E.H., and P.N. M.C.M. performed the statistical analysis and wrote the initial draft with 
supervision from W.N., S.E.H. and P.N. Ø.K. and G.D.S. contributed with invaluable support 
for data analyses, interpretation of findings and critical revision of the manuscript. W.N. and 
M.C.M. obtained the financial support. All authors had full access to data, reviewed and 
approved the final version of the article submitted for publication. M.C.M. will act as the 
guarantor of the manuscript. The references have been checked for accuracy and 
completeness by M.C.M.The authors are grateful to all families participating in the 
Norwegian Mother and Child Cohort Study.  
 
Competing of interest: All authors report no conflict of interest. 
 
  
Page 17 of 28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
18 
 
References 
1. Akinbami L. The state of childhood asthma, United States, 1980-2005. Adv Data 2006:1-24. 
2. Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence 
and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in 
Childhood (ISAAC). Thorax  2009;64:476-83. 
3. Cheelo M, Lodge CJ, Dharmage SC, Simpson JA, Matheson M, Heinrich J, et al. Paracetamol 
exposure in pregnancy and early childhood and development of childhood asthma: a systematic review 
and meta-analysis. Arch Dis Child 2014 ; 100: 81-9. 
4. Etminan M, Sadatsafavi M, Jafari S, Doyle-Waters M, Aminzadeh K, Fitzgerald JM. 
Acetaminophen use and the risk of asthma in children and adults: a systematic review and 
metaanalysis. Chest 2009;136:1316-23. 
5. Eyers S, Weatherall M, Jefferies S, Beasley R. Paracetamol in pregnancy and the risk of 
wheezing in offspring: a systematic review and meta-analysis. Clin Exp Allergy 2011;41:482-9. 
6. Bakkeheim E, Mowinckel P, Carlsen KH, Haland G, Carlsen KC. Paracetamol in early 
infancy: the risk of childhood allergy and asthma. Acta Paediatr 2011;100:90-6. 
7. Shaheen SO, Newson RB, Ring SM, Rose-Zerilli MJ, Holloway JW, Henderson AJ. Prenatal 
and infant acetaminophen exposure, antioxidant gene polymorphisms, and childhood asthma. J Allergy 
Clin Immunol 2010;126:1141-8. 
8. Sordillo JE, Scirica CV, Rifas-Shiman SL, Gillman MW, Bunyavanich S, Camargo CA, Jr., et 
al. Prenatal and infant exposure to acetaminophen and ibuprofen and the risk for wheeze and asthma in 
children. J Allergy Clin Immunol  2015;135:441-8. 
9. The Norwegian Medicines Agency. Use of prescription free pain killers. 2015. 
http://www.legemiddelverket.no/Bruk_og_raad/raadtilforbruker/Smertestillende/Sider/default.aspx. 
(Accessed 25.02.15). 
10. Shaheen SO, Newson RB, Henderson AJ, Headley JE, Stratton FD, Jones RW, et al. Prenatal 
paracetamol exposure and risk of asthma and elevated immunoglobulin E in childhood. Clin Exp 
Allergy 2005;35:18-25. 
11. Rebordosa C, Kogevinas M, Sorensen HT, Olsen J. Pre-natal exposure to paracetamol and risk 
of wheezing and asthma in children: a birth cohort study. Int J Epidemiol 2008;37:583-90. 
12. Richmond RC, Al-Amin A, Smith GD, Relton CL. Approaches for drawing causal inferences 
from epidemiological birth cohorts: a review. Early Hum Dev 2014;90:769-80. 
13. Smith GD. Assessing intrauterine influences on offspring health outcomes: can 
epidemiological studies yield robust findings? Basic Clin Pharmacol Toxicol 2008;102:245-56. 
14. Magnus P, Irgens LM, Haug K, Nystad W, Skjaerven R, Stoltenberg C. Cohort profile: the 
Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol 2006;35:1146-50. 
15. Nilsen RM, Vollset SE, Gjessing HK, Skjaerven R, Melve KK, Schreuder P, et al. Self-
selection and bias in a large prospective pregnancy cohort in Norway. Paediatr Perinat Epidemiol 
2009;23:597-608. 
16. Kreiner-Moller E, Sevelsted A, Vissing NH, Schoos AM, Bisgaard H. Infant acetaminophen 
use associates with early asthmatic symptoms independently of respiratory tract infections: the 
Copenhagen Prospective Study on Asthma in Childhood 2000 (COPSAC(2000)) cohort. J Allergy 
Clin Immunol 2012;130:1434-6. 
17. Lowe AJ, Carlin JB, Bennett CM, Hosking CS, Allen KJ, Robertson CF, et al. Paracetamol 
use in early life and asthma: prospective birth cohort study. BMJ 2010;341:c4616. 
18. Schnabel E, Heinrich J. Respiratory tract infections and not paracetamol medication during 
infancy are associated with asthma development in childhood. J Allergy Clin Immunol 2010;126:1071-
3. 
19. Wickens K, Beasley R, Town I, Epton M, Pattemore P, Ingham T, et al. The effects of early 
and late paracetamol exposure on asthma and atopy: a birth cohort. Clin Exp Allergy 2011;41:399-406. 
20. Simon RA, Dazy KM, Waldram JD. Aspirin-exacerbated respiratory disease: characteristics 
and management strategies. Expert Rev Clin Immunol 2015;11:805-17. 
21. Cookson H, Granell R, Joinson C, Ben-Shlomo Y, Henderson AJ. Mothers' anxiety during 
pregnancy is associated with asthma in their children. J Allergy Clin Immunol 2009;123:847-53. 
Page 18 of 28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
19 
 
22. Fang F, Hoglund CO, Arck P, Lundholm C, Langstrom N, Lichtenstein P, et al. Maternal 
bereavement and childhood asthma-analyses in two large samples of Swedish children. PLoS One 
2011;6:e27202. 
23. Kozyrskyj AL, Mai XM, McGrath P, Hayglass KT, Becker AB, Macneil B. Continued 
exposure to maternal distress in early life is associated with an increased risk of childhood asthma. Am 
J Respir Crit Care Med 2008;177:142-7. 
24. Wright RJ, Cohen S, Carey V, Weiss ST, Gold DR. Parental stress as a predictor of wheezing 
in infancy: a prospective birth-cohort study. Am J Respir Crit Care Med 2002;165:358-65. 
25. Shaheen SO, Newson RB, Smith GD, Henderson AJ. Prenatal paracetamol exposure and 
asthma: further evidence against confounding. International journal of epidemiology. 2010;39:790-4. 
26. Grainge CL, Davies DE. Epithelial injury and repair in airways diseases. Chest 
2013;144:1906-12. 
27. Nassini R, Materazzi S, Andre E, Sartiani L, Aldini G, Trevisani M, et al. Acetaminophen, via 
its reactive metabolite N-acetyl-p-benzo-quinoneimine and transient receptor potential ankyrin-1 
stimulation, causes neurogenic inflammation in the airways and other tissues in rodents. FASEB J 
2010;24:4904-16. 
28. Patelarou E, Giourgouli G, Lykeridou A, Vrioni E, Fotos N, Siamaga E, et al. Association 
between biomarker-quantified antioxidant status during pregnancy and infancy and allergic disease 
during early childhood: a systematic review. Nutr Rev 2011;69:627-41. 
29. Devereux G, Turner SW, Craig LC, McNeill G, Martindale S, Harbour PJ, et al. Low maternal 
vitamin E intake during pregnancy is associated with asthma in 5-year-old children. Am J Respir Crit 
Care Med 2006;174:499-507. 
30. Martindale S, McNeill G, Devereux G, Campbell D, Russell G, Seaton A. Antioxidant intake 
in pregnancy in relation to wheeze and czema in the first two years of life. Am J Respir Crit Care 
Med 2005;171:121-8. 
31. Levy S, Volans G. The use of analgesics in patients with asthma. Drug Saf 2001;24:829-41. 
32. Furu K, Karlstad O, Skurtveit S, Haberg SE, Nafstad P, London SJ, et al. High validity of 
mother-reported use of antiasthmatics among children: a comparison with a population-based 
prescription database. J Clin Epidemiol 2011;64:878-84. 
33. Ebrahim S, Davey Smith G. Commentary: Should we always deliberately be non-
representative? Int J Epidemiol 2013;42:1022-6. 
34. Richiardi L, Pizzi C, Pearce N. Commentary: Representativeness is usually not necessary and 
often should be avoided. Int J Epidemiol 2013;42:1018-22. 
35. Rothman K, Hatch E, Gallacher J. Representativeness is not helpful in studying heterogeneity 
of effects across subgroups. Int J Epidemiol 2014;43:633-4. 
  
Page 19 of 28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
20 
 
Figure legends: 
 
Figure 1 Illustration of sample selection 
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Table 1. Characteristics by prenatal and infant paracetamol exposure 
(N=53,169) 
Characteristics  
 
 
 
n 
No 
exposure 
 
 
(%) 
Prenatal 
exposure 
only 
 
(%) 
Infant 
exposure 
only 
 
(%) 
Both 
prenatal and 
infant 
exposure  
(%) 
Maternal age, years      
   <25 4,758 36.0 30.1 15.2 18.8 
   25-29 17,725 36.8 27.8 15.7 19.7 
   30-34 21,137 37.0 27.8 15.7 19.5 
   >=35 9,549 40.4 27.3 14.9 17.4 
Maternal parity       
    Primiparous 25,486 40.6 27.3 15.5 16.6 
    1 18,158 33.6 27.9 16.1 22.4 
    2 7,488 35.4 29.8 14.5 20.3 
    3 or more 2,037 38.9 28.8 14.3 17.9 
Maternal education       
    Less than high school 2,910 38.2 27.9 14.2 19.8 
    High school 14,175 37.6 29.9 14.1 18.4 
    Up to 4 years of college 22,841 36.1 27.7 15.9 20.3 
    More than 4 years of college 13,046 39.5 26.1 16.7 17.8 
    Missing 197 37.6 29.4 16.2 16.8 
Maternal pre-pregnancy BMI      
    Underweight (<18.5) 1,520 41.7 25.5 15.9 16.9 
    Normal weight (18.5-24.9) 34,625 39.2 26.8 16.0 18.0 
    Overweight (25-29.9) 11,247 33.8 30.1 14.9 21.2 
    Obese (>=30) 4,626 30.7 32.1 13.3 23.9 
    Missing 1,151 42.1 26.2 14.9 16.9 
Maternal asthma       
    No  49,338 38.2 27.6 15.5 18.7 
    Yes 3,831 28.5 31.9 15.2 24.4 
Maternal RTI/influenza during 
pregnancy 
     
    No  21,248 45.8 22.8 17.7 13.8 
    Yes 31,921 31.9 31.3 14.1 22.7 
Maternal fever during pregnancy      
    No  44,359 41.1 25.3 16.9 16.7 
    Yes 8,810 18.9 41.0 8.6 31.5 
Maternal pain during pregnancy      
    No  12,329 53.7 17.5 18.9 10.0 
    Yes 40,840 32.6 31.1 14.5 21.9 
Maternal smoking during 
pregnancy  
     
    No 48,947 37.8 27.6 15.6 19.0 
    Yes 3,970 32.6 31.8 14.1 21.4 
    Missing 
 
252 38.5 31.8 11.1 18.7 
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Child gender      
   Male 27,193 37.1 26.6 16.5 19.8 
   Female 25,976 37.8 29.3 14.5 18.4 
Child birth weight, grams      
    <2,500 1,332 38.5 28.8 12.8 19.9 
    2,500-2,999 4,505 39.6 26.3 16.0 18.1 
    3,000-3,499 15,523 38.3 27.6 15.6 18.5 
    3,500-4,000 20,023 37.1 27.9 15.7 19.3 
    >4000 11,764 36.0 28.8 15.2 20.0 
    Missing 22 31.8 27.3 13.6 27.3 
Child breastfeeding the first 6 
months  
     
   None 1,360 34.6 29.8 13.4 22.2 
   Partial 28,191 35.3 28.5 15.6 20.7 
   Exclusive 23,618 40.2 27.1 15.6 17.1 
Child RTI the first 6 months      
    No 11,441 47.4 32.1 10.0 10.6 
    Yes 40,343 34.3 26.6 17.2 21.8 
    Missing 1,385 46.8 30.8 11.7 10.8 
Child BMI at 6 months      
    <16.1 12,573 38.4 28.0 15.1 18.6 
    16.1-17.0 12,559 37.2 28.1 15.5 19.2 
    17.1-18.0 12,743 37.1 28.4 15.4 19.1 
    >18.1 12,520 36.8 27.1 16.2 20.0 
     Missing 2,774 39.3 28.2 14.8 17.7 
Prenatal and infant antibiotic 
exposure 
     
    None 44,143 39.1 27.2 15.7 18.0 
    Prenatal only 6,387 28.8 33.7 12.9 24.6 
    Infant only 2,188 31.8 25.3 19.2 23.7 
    Prenatal and infant 451 23.7 31.0 14.2 31.0 
 
BMI-body mass index; RTI - respiratory tract infections      
The frequencies in this table are based on the study sample used to examine current asthma at 
3 years.  
 
RTI/influenza during pregnancy included maternal report of upper respiratory tract infections 
(ear, throat, sinus infections and/or colds) lower respiratory tract infections (pneumonia and/or 
bronchitis) and/or influenza.  
 
Pain during pregnancy included maternal report of pelvic prolapse, back pain, neck/shoulder 
pain, migraine/head ache, fibromyalgia and/or unspecified muscle pain.  
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Table 2. The association of prenatal and infant paracetamol exposure with development of asthma   
 
a
 Associations adjusted for maternal age, parity, education, pre-pregnancy body-mass index, smoking during pregnancy, asthma, respiratory tract 
infections/influenza during pregnancy, fever during pregnancy, pain during pregnancy and antibiotic use during pregnancy, in addition to the 
child’s gender, birth weight, breastfeeding the first 6 months of life, respiratory tract infections by 6 months, body mass index at 6 months and 
use of antibiotics by 6 months.  
 
RTI/influenza during pregnancy included maternal report of upper respiratory tract infections (ear, throat, sinus infections and/or colds) lower 
respiratory tract infections (pneumonia and/or bronchitis) and/or influenza.  
 
Pain during pregnancy included maternal report of pelvic prolapse, back pain, neck/shoulder pain, migraine/head ache, fibromyalgia and/or 
unspecified muscle pain.  
Current asthma at 3 years  (N=53,169) 
Prenatal and infant paracetamol exposure N % case Unadjusted RR(95%CI) Adjusted RR (95% CI)
a
 
    No exposure 19,912 4.4 1 1 
    Prenatal exposure only 14,837 5.9 1.33 (1.21-1.46) 1.13 (1.02-1.25) 
    Infant exposure only 8,246 6.5 1.47 (1.32-1.63) 1.29 (1.16- 1.45) 
    Both prenatal and infant exposure 10,174 7.5 1.71 (1.55-1.88) 1.27 (1.14- 1.41) 
Current asthma at 7 years (N=25,394) 
Prenatal and infant paracetamol exposure N % case Unadjusted RR(95%CI) Adjusted RR (95% CI)
a
 
    No exposure 9,905 3.9 1 1 
    Prenatal exposure only 7,240 5.6 1.44 (1.26-1.66) 1.27 (1.09- 1.47) 
    Infant exposure only 3,763 5.2 1.35 (1.14- 1.60) 1.24 (1.03 - 1.48) 
    Both prenatal and infant exposure 4,486 6.9 1.78 (1.54-  2.06) 1.49 (1.27- 1.75) 
Dispensed asthma medications  at 7 years (N=45,607) 
Prenatal and infant paracetamol exposure N % case Unadjusted RR(95%CI) Adjusted RR (95% CI)
a
 
    No exposure 17,840 3.9 1 1 
    Prenatal exposure only 12,974 5.2 1.33 (1.20- 1.48) 1.17 (1.04- 1.31) 
    Infant exposure only 6,708 5.2 1.33 (1.17- 1.51) 1.27 (1.11-1.46) 
    Both prenatal and infant exposure 8,085 5.8 1.50 (1.33- 1.68) 1.26 (1.10- 1.43) 
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Infant paracetamol exposure reflects the child’s use of paracetamol the first 6 months of life.  
 
The results presented are based on a complete case analysis. A total of 47,173 children were included in the multivariable analysis of current 
asthma at 36 months, 22,102 children in the analysis of current asthma at 7 years and 38,677 in the analysis of dispensed asthma medications at 7 
years.   
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Table 3. The association of maternal indications and use of paracetamol during pregnancy with development of asthma in the offspring  
Current asthma at 3 years (N=45,641) 
Exposure n % cases Unadjusted RR (95%CI) Adjusted RR (95% CI)
a
 
Did not use 
paracetamol 
Did not experience indications 4,660 3.4 1 1 
Experienced RTI/influenza only 3,623 3.8 1.12 (0.90- 1.41) 1.07 (0.85- 1.34) 
Experienced fever 
b
 659 3.1 0.91 (0.58-1.44) 0.88 (0.56- 1.40) 
Experienced pain  only 8,499 5.5 1.63 (1.36- 1.95) 1.47 (1.23- 1.76) 
Experienced more than one indication 10,717 5.9 1.74 (1.47- 2.07) 1.60 (1.35- 1.91) 
Used 
paracetamol 
For RTI/influenza  only 1,817 5.7 1.70 (1.33- 2.17) 1.51 (1.18- 1.93) 
For fever  
b
 3,234 6.5 1.91 (1.56- 2.35) 1.58 (1.28- 1.94) 
For pain  only 9,575 6.9 2.06 (1.74- 2.45) 1.73 (1.46- 2.06) 
For more than one indication 2,857 7.8 2.32 (1.90- 2.84) 1.94 (1.58- 2.37) 
Current asthma at 7 years (N=21,910) 
Exposure n % cases Unadjusted RR (95%CI) Adjusted RR (95% CI)
a
 
Did not use 
paracetamol 
Did not experience indications 2,377 3.5 1 1 
Experienced RTI/influenza  only 1,810 4.3 1.23 (0.90- 1.68) 1.15 (0.83- 1.58) 
Experienced fever  
b
 316 2.2 0.64 (0.30- 1.38) 0.65 (0.30- 1.38) 
Experienced pain  only 4,075 4.5 1.29 (1.00- 1.67) 1.18 (0.90- 1.53) 
Experienced more than one indication 5,090  4.6 1.32 (1.03- 1.70) 1.23 (0.95- 1.58) 
Used 
paracetamol 
For RTI/influenza  only 877 5.4 1.55 (1.09-2.21) 1.39 (0.97- 1.99) 
For fever  
b
 1,418   5.5 1.58 (1.16- 2.15) 1.34 (0.98- 1.85) 
For pain  only 4,623 6.2 1.81 (1.42- 2.30) 1.53 (1.19-1.96) 
For more than one indication 1,324 7.8 2.25 (1.69- 2.99) 1.91 (1.43- 2.55) 
Dispensed asthma medications at 7 years (N=39,157) 
Exposure n % cases Unadjusted RR (95%CI) Adjusted RR (95% CI)
a
 
Did not use 
paracetamol 
Did not experience indications 4,107 3.5 1 1 
Experienced RTI/influenza  only 3,067 3.0 0.87 (0.67- 1.13) 0.83 (0.64- 1.08) 
Experienced fever  
b
 558 2.2 0.62 (0.34- 1.11) 0.63 (0.35- 1.14) 
Experienced pain  only 7,548 4.5 1.28 (1.06- 1.55) 1.21 (0.99- 1.47) 
Experienced more than one indication 9,267 5.0 1.42 (1.18- 1.71) 1.36 (1.13-1.65) 
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RTI- respiratory tract infections 
 
a
 Associations adjusted for maternal age, parity, education, pre-pregnancy body-mass index, smoking during pregnancy, asthma and antibiotic 
use during pregnancy 
 
b
 The group who reported fever or use of paracetamol for fever were allowed to also report RTI/influenza or use of paracetamol for 
RTI/influenza. All other categories are mutually exclusive.  
 
RTI/influenza during pregnancy included maternal report of upper respiratory tract infections (ear, throat, sinus infections and/or colds) lower 
respiratory tract infections (pneumonia and/or bronchitis) and/or influenza.  
 
Pain during pregnancy included maternal report of pelvic prolapse, back pain, neck/shoulder pain, migraine/head ache, fibromyalgia and/or 
unspecified muscle pain.  
 
This analysis excluded individuals who used paracetamol for other/unspecified reason. This included 7,528 children in the evaluated of current 
asthma at 3 years, 3,484 children in the evaluation of current asthma at 7 years and 6,450 children in the evaluation of dispensed asthma 
medications at 7 years.  
The results presented are based on a complete case analysis. A total of 43,789 children were included in the multivariable analysis of current 
asthma at 36 months, 20,800 children in the analysis of current asthma at 7 years and 37,783 in the analysis of dispensed asthma medications at 7 
years.   
Used 
paracetamol 
For respiratory RTI /influenza only 1,452 4.6 1.33 (1.00- 1.76) 1.24 (0.93- 1.66) 
For fever  
b
 2,509 5.6 1.60 (1.28- 2.01) 1.41 (1.12- 1.79) 
For pain only 8,263 5.9 1.71 (1.42- 2.05) 1.51 (1.25- 1.83) 
For more than one indication 2,386 6.4 1.83 (1.46- 2.29) 1.59 (1.26- 2.01) 
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Table 4. The association of maternal use of ibuprofen and paracetamol during pregnancy with development of asthma in the offspring 
 
a
 Associations adjusted for maternal age, parity, education, pre-pregnancy body-mass index, smoking during pregnancy, asthma, respiratory tract 
infections/influenza during pregnancy, pain during pregnancy, fever during pregnancy and antibiotic use during pregnancy 
 
The results presented are based on a complete case analysis. A total of 51,011 children were included in the multivariable analysis of current 
asthma at 36 months, 24,114 children in the analysis of current asthma at 7 years and 44,009 in the analysis of dispensed asthma medications at 7 
years.  
 
Current asthma at 3 years  (N=53,169) 
Ibuprofen and paracetamol use during pregnancy N % case Unadjusted RR (95%CI) Adjusted RR (95% CI)
a
 
   Neither 27,392 5.0 1 1 
   Only ibuprofen 766 7.0 1.41 (1.08- 1.84) 1.31 (1.00,1.72) 
   Only paracetamol 22,675 6.5 1.32 (1.23- 1.42) 1.11 (1.02, 1.19) 
   Both ibuprofen and paracetamol 2,336 6.6 1.34 (1.14- 1.58) 1.10 (0.93, 1.30) 
Current asthma at 7 years (N=25,394) 
Ibuprofen and paracetamol use during pregnancy N % case Unadjusted RR (95%CI) Adjusted RR (95% CI)
a
 
   Neither 13,290 4.2 1 1 
   Only ibuprofen 378 4.9 1.16 (0.74- 1.83) 1.16 (0.73, 1.83) 
   Only paracetamol 10,608 6.1 1.44 (1.29- 1.61) 1.26 (1.12, 1.43) 
   Both ibuprofen and paracetamol 1,118 6.1 1.45 (1.14- 1.86) 1.28 (1.00, 1.65) 
Dispensed asthma medications  at 7 years (N=45,607) 
Ibuprofen and paracetamol use during pregnancy N % case Unadjusted RR (95%CI) Adjusted RR (95% CI)
a
 
   Neither 23,839 4.2 1 1 
   Only ibuprofen 709 4.8 1.13 (0.81- 1.58) 1.02 (0.73, 1.44) 
   Only paracetamol 19,139 5.5 1.29 (1.19- 1.40) 1.12 (1.03, 1.23) 
   Both ibuprofen and paracetamol 1,920 5.3 1.24 (1.02- 1.52) 1.03 (0.83, 1.26) 
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Figure 1 Illustration of sample selection  
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